Drug Name: | Astemizole (68844-77-9) |
---|---|
PubChem ID: | 2247 |
SMILES: | COC1=CC=C(C=C1)CCN2CCC(CC2)NC3=NC4=CC=CC=C4N3CC5=CC=C(C=C5)F |
InchiKey: | GXDALQBWZGODGZ-UHFFFAOYSA-N |
Therapeutic Category: |
Molecular Weight (dalton) | : | 458.581 |
LogP | : | 5.3513 |
Ring Count | : | 4 |
Hydrogen Bond Acceptor Count | : | 5 |
Hydrogen Bond Donor Count | : | 1 |
Total Polar Surface Area | : | 42.32 |
This panel provides information on interacting drugs and their ADRs along with references
Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
---|---|---|---|---|
Ketoconazole (65277-42-1) | Torsade De Pointes | Synergistic | In vitro studies have shown that ketoconazole inhibits the metabolism of astemizole. | Combined use of astemizole and ketoconazole resulting in torsade de pointes |
Quinine (130-95-0) | Arrhythmia | Synergistic | Uncertain | Quinine may trigger torsades de pointes during astemizole therapy |
This panel provides drug-protein interaction and their ADRs along with references
Toxicity | Interacting Protein | Mechanism | Reference |
---|---|---|---|
Arrhythmias | Potassium voltage-gated channel subfamily H member 2 (Q12809) | Keynote review: in vitro safety pharmacology profiling: an essential tool for successful drug development |
This panel provides drug-food interactions and their ADRs along with references
Food | Toxicity | Reference |
---|
This panel provides information on metabolites and their ADRs along with references
Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
---|
This panel provides information on drug category